|
|
Vaccine Detail
|
Pam3CSK4-MUC1-(Rha)3 Liposomal Vaccine |
| Vaccine Information |
- Vaccine Name: Pam3CSK4-MUC1-(Rha)3 Liposomal Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Type: Conjugate vaccine
- Status: Research
- Host Species for Licensed Use: Mouse
- Antigen: MUC1 (Hossain et al., 2020)
- Immunization Route: Intraperitoneal injection (i.p.)
- Description: A single molecular construct conjugate vaccine combining Pam3CSK4 lipopeptide, MUC1-VNTR tumor antigen, and tri-rhamnose targeting ligand, covalently linked and delivered via liposomes. The vaccine exploits natural human anti-rhamnose antibodies to target dendritic cells, stimulating both humoral and cellular immune responses against MUC1-expressing tumor cells. Vaccination enhanced anti-MUC1 antibody production and significantly increased antigen-specific CD4+ T cell proliferation (p < 0.001) in rhamnose-targeted groups. MUC1 antigen, a membrane-bound glycoprotein hypo-glycosylated in various cancers, is overexpressed aberrantly in cancers such as breast, prostate, and ovary. No external adjuvant is required as Pam3CSK4 serves as a self-adjuvanting TLR-2 ligand built into the construct (Hossain et al., 2020).
|
| Host Response |
|
|
| References |
Hossain et al., 2020: Hossain MK, Vartak A, Sucheck SJ, Wall KA. Synthesis and Immunological Evaluation of a Single Molecular Construct MUC1 Vaccine Containing l-Rhamnose Repeating Units. Molecules (Basel, Switzerland). 2020; 25(14); . [PubMed: 32659971].
|
|
